Three year results from the SPECTRUM registry: 702 eyes treated with a Schlemm’s Canal Microstent as a standalone procedure for glaucoma
Free Paper Details
First Author: L.Au UK
The purpose of this evaluation is to present outcomes in the 702 eyes (from 575 patients) who underwent Hydrus implantation as a standalone treatment for glaucoma.
The study population consisted of pateints with a glaucoma diagnosis drawn from 50 clinical sites located in 17 countires in Europe, Asia, Australia, South and Central America, and Canada.
Patients were treated according to the surgeon’s standard of care and results were entered into an online database. Mean age was 70 years old and 50% of subjects were female. Subjects were 75% Caucasian, 12% Hispanic, 5% Black and 5% Asian. Prior ocular history included 36% with prior laser trabeculoplasty and 16% with prior incisional glaucoma surgery. POAG was the most common form of glaucoma (76%) but other types of glaucoma were represented, including pseudoexfoliation (7%), pigmentary (3%) and angle closure (4%). In terms of lens status, 34% were phakic and 65% pseudophakic.
Results demonstrate significant reduction in IOP and medications for at least 3 years postoperative. Baseline mean IOP was 21.1 mmHg on 2.6 categories of glaucoma medications. Mean IOP reduction was 4.9 mmHg at 1 year, 5.7 mmHg at 2 years and 6.1 mmHg at 3 years (p < 0.05 for all time points). Mean reduction in glaucoma medications was 1.1 meds at 1 year, 1.0 meds at 2 years and 0.9 meds at 3 years (p < 0.05 for all time points). The rate of adverse events was approximately 1% intraoperative and 7% cumulative through 3 years postoperative.
The Hydrus® Microstent significantly reduced both IOP and glaucoma medications as a standalone treatment. The results were maintained for at least three years in a large and diverse population. There were no significant safety concerns.
... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a competing company, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a competing company